New Procedure Effective Against Lower Back Pain
Oct. 19, 2000 -- For people suffering from chronic low back pain that is not easily diagnosed, there may be hope on the very near horizon.
A relatively new procedure known as intradiscal thermal annuloplasty (IDTA) seems to be effective in treating some forms of back pain and may offer a new treatment option.
Back pain has so many possible causes, sorting out the specific cause of one person's pain can be a real challenge. That's why most of the time physicians try conservative treatment first. Patients receive non-steroidal anti-inflammatory medicines (NSAIDs) like ibuprofen or aspirin, muscle relaxants, physical therapy and home-based stretching routines.
However, if the pain is still present after giving those methods a good try, more tests are needed. One likely source of pain is the fibrous discs separating the spinal vertebrae. The physician will probably use magnetic resonance imaging (MRI) to check for a disc pressing on a nerve, or a possible tumor. He will also try discography, in which dye is injected within the disk.
One possible cause of persistent back pain is degeneration of the disk's central pulp. If that is the problem, then IDTA may be helpful, according to research published in the Oct. 15 issue of the journal Spine.
In this procedure an electrode is threaded through a needle around the central part of the disc and then heated to coagulate the damaged part of the disc and destroy the nerve endings that transmit pain signals. "If someone has intrusive chronic back pain that interferes with work, family life and play, if they've tried physical therapy and medications without relief, they need to know there is now a needle-based intervention that may help them," says study author Michael Karasek, MD. "Before this, the only other available option would have been major surgery." Karasek is medical director of the Northwest Spine Group in Eugene, Ore.
IDTA was approved for general use by the FDA in the spring of 1998. At present, only some insurers cover it, while others say it is still too experimental. "Insurers today are quite strict in adopting new technologies. They want to see years of data with multiple studies proving efficacy and safety," Karasek says. "We feel this study goes a long way toward satisfying those requirements. My understanding is [that] all the major carriers are closely examining this issue, because they understand this marks the advent of a new era in spine treatment."